Annual New Treatments in Chronic Liver Disease 2011

This CME conference will review new medications and therapies that are available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, autoimmune hepatitis, primary biliary cirrhosis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There will be a fundamental change in treatment of chronic renal hepatitis c in 2011 with the addition of direct-acting antiviral (DAAs) drugs to current standard of care. There will be two separate lectures devoted to this topic this year. The first will be on triple therapies which will be approved in 2011. The second will be on combination therapies using two or more DAA’s.